Literature DB >> 33607217

N-acetyl-lysyltyrosylcysteine amide, a novel systems pharmacology agent, reduces bronchopulmonary dysplasia in hyperoxic neonatal rat pups.

Ru-Jeng Teng1, Xigang Jing1, Dustin P Martin2, Neil Hogg3, Aaron Haefke4, Girija G Konduri1, Billy W Day5, Stephen Naylor5, Kirkwood A Pritchard6.   

Abstract

Bronchopulmonary dysplasia (BPD) is caused primarily by oxidative stress and inflammation. To induce BPD, neonatal rat pups were raised in hyperoxic (>90% O2) environments from day one (P1) until day ten (P10) and treated with N-acetyl-lysyltyrosylcysteine amide (KYC). In vivo studies showed that KYC improved lung complexity, reduced myeloperoxidase (MPO) positive (+) myeloid cell counts, MPO protein, chlorotyrosine formation, increased endothelial cell CD31 expression, decreased 8-OH-dG and Cox-1/Cox-2, HMGB1, RAGE, TLR4, increased weight gain and improved survival in hyperoxic pups. EPR studies confirmed that MPO reaction mixtures oxidized KYC to a KYC thiyl radical. Adding recombinant HMGB1 to the MPO reaction mixture containing KYC resulted in KYC thiylation of HMGB1. In rat lung microvascular endothelial cell (RLMVEC) cultures, KYC thiylation of RLMVEC proteins was increased the most in RLMVEC cultures treated with MPO + H2O2, followed by H2O2, and then KYC alone. KYC treatment of hyperoxic pups decreased total HMGB1 in lung lysates, increased KYC thiylation of HMGB1, terminal HMGB1 thiol oxidation, decreased HMGB1 association with TLR4 and RAGE, and shifted HMGB1 in lung lysates from a non-acetylated to a lysyl-acetylated isoform, suggesting that KYC reduced lung cell death and that recruited immune cells had become the primary source of HMGB1 released into the hyperoxic lungs. MPO-dependent and independent KYC-thiylation of Keap1 were both increased in RLMVEC cultures. Treating hyperoxic pups with KYC increased KYC thiylation and S-glutathionylation of Keap1, and Nrf2 activation. These data suggest that KYC is a novel system pharmacological agent that exploits MPO to inhibit toxic oxidant production and is oxidized into a thiyl radical that inactivates HMGB1, activates Nrf2, and increases antioxidant enzyme expression to improve lung complexity and reduce BPD in hyperoxic rat pups.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bronchopulmonary dysplasia; High mobility group box-1; Kelch-like ECH-Associated protein 1; Myeloperoxidase; Nuclear factor erythroid 2-related factor 2

Mesh:

Substances:

Year:  2021        PMID: 33607217      PMCID: PMC8009865          DOI: 10.1016/j.freeradbiomed.2021.02.006

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  38 in total

1.  Quantifying trifluoroacetic acid as a counterion in drug discovery by 19F NMR and capillary electrophoresis.

Authors:  Michael J Little; Norman Aubry; Marie-Eve Beaudoin; Nathalie Goudreau; Steven R LaPlante
Journal:  J Pharm Biomed Anal       Date:  2006-12-04       Impact factor: 3.935

2.  Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1).

Authors:  Huan Yang; Peter Lundbäck; Lars Ottosson; Helena Erlandsson-Harris; Emilie Venereau; Marco E Bianchi; Yousef Al-Abed; Ulf Andersson; Kevin J Tracey; Daniel J Antoine
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

3.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release.

Authors:  Huan Yang; Hulda S Hreggvidsdottir; Karin Palmblad; Haichao Wang; Mahendar Ochani; Jianhua Li; Ben Lu; Sangeeta Chavan; Mauricio Rosas-Ballina; Yousef Al-Abed; Shizuo Akira; Angelika Bierhaus; Helena Erlandsson-Harris; Ulf Andersson; Kevin J Tracey
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-14       Impact factor: 11.205

4.  Nitrogen dioxide radical generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid peroxidation of low density lipoprotein.

Authors:  J Byun; D M Mueller; J S Fabjan; J W Heinecke
Journal:  FEBS Lett       Date:  1999-07-23       Impact factor: 4.124

Review 5.  Association of Nrf2 with airway pathogenesis: lessons learned from genetic mouse models.

Authors:  Hye-Youn Cho; Steven R Kleeberger
Journal:  Arch Toxicol       Date:  2015-07-21       Impact factor: 5.153

Review 6.  Developmental regulation of antioxidant enzymes and their impact on neonatal lung disease.

Authors:  Sara K Berkelhamer; Kathryn N Farrow
Journal:  Antioxid Redox Signal       Date:  2014-02-06       Impact factor: 8.401

7.  Inhibition of myeloperoxidase by N-acetyl lysyltyrosylcysteine amide reduces experimental autoimmune encephalomyelitis-induced injury and promotes oligodendrocyte regeneration and neurogenesis in a murine model of progressive multiple sclerosis.

Authors:  Guoliang Yu; Shikan Zheng; Hao Zhang
Journal:  Neuroreport       Date:  2018-02-07       Impact factor: 1.837

8.  The role of neutrophil myeloperoxidase in models of lung tumor development.

Authors:  Amy L Rymaszewski; Everett Tate; Joannes P Yimbesalu; Andrew E Gelman; Jason A Jarzembowski; Hao Zhang; Kirkwood A Pritchard; Haris G Vikis
Journal:  Cancers (Basel)       Date:  2014-05-09       Impact factor: 6.639

9.  Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke.

Authors:  Guoliang Yu; Ye Liang; Ziming Huang; Deron W Jones; Kirkwood A Pritchard; Hao Zhang
Journal:  J Neuroinflammation       Date:  2016-05-24       Impact factor: 8.322

10.  Inhibition of myeloperoxidase increases revascularization and improves blood flow in a diabetic mouse model of hindlimb ischaemia.

Authors:  Dorothee Weihrauch; Dustin P Martin; Deron Jones; John Krolikowski; Janine Struve; Stephen Naylor; Kirkwood A Pritchard
Journal:  Diab Vasc Dis Res       Date:  2020 Mar-Apr       Impact factor: 3.291

View more
  1 in total

1.  Role of endoplasmic reticulum stress in impaired neonatal lung growth and bronchopulmonary dysplasia.

Authors:  Kirkwood A Pritchard; Xigang Jing; Michelle Teng; Clive Wells; Shuang Jia; Adeleye J Afolayan; Jason Jarzembowski; Billy W Day; Stephen Naylor; Martin J Hessner; G Ganesh Konduri; Ru-Jeng Teng
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.